Hosted on MSN5h
Metastasis-Directed Therapy for Prostate Cancer a Clear Winner in Meta-Analysis
Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...
Cure Today7h
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
UroToday7h
ASCO GU 2025: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate Cancer with Salvage Surgery
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...
Business Wire11h
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...
MedPage Today13h
What's the Better Option for High-Risk Prostate Cancer -- Radiation or Surgery?
SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...
The American Journal of Managed Care14h
The Impact of ADT for Prostate Cancer on Survival and Patient Well-Being
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
UroToday23h
ASCO GU 2025: Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.